IMMUNE THROMBOCYTOPENIAS

Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice

IMMUNE THROMBOCYTOPENIAS ,

II Zotova, SV Gritsaev, ER Shilova, NA Potikhonova, KМ Abdulkadyrov, AV Chechetkin

Russian Scientific Research Institute of Hematology and Transfusiology under the Federal Medico-Biological Agency, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

For correspondence: Irina Ivanovna Zotova, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024; Tel: +7(812)271-44-31; e-mail: hemzot@mail.ru

For citation: Zotova II, Gritsaev SV, Shilova ER, et al. Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice. Clinical oncohematology. 2017;10(1):93–100 (In Russ).

DOI: 10.21320/2500-2139-2017-10-1-93-100

ABSTRACT

Background & Aims. The use of thrombopoietin receptor agonists (aTPO-r) is a new approach to the treatment of patients with idiopathic thrompocytopenic purpura (ITP) irresponsive to other methods. Data on the efficacy and safety of aTPO-r outside the frames of clinical trials are limited. The aim of the study is to evaluate the efficacy of the therapy in the routine clinical practice as the second and subsequent lines of therapy, as well as the frequency and nature of complications of the treatment in chronic ITP patients.

Methods. Data on 58 adult patients (median age: 56 years) with chronic ITP were retrospectively evaluated; 43 (74 %) of them were treated with romiplostim and 15 (26 %) patients received eltrombopag. Two or more lines of prior therapy were ineffective in 19 (33 %) patients (14 from the romiplostim group and 5 from the eltrombopag group). aTPO-r was prescribed and adjusted according to the prescription guidelines. The efficacy of the treatment was assessed based on the platelet response and the possibility of achieving a sustained response after discontinuation of the therapy. Hemorrhagic manifestations were classified according to the WHO bleeding scale. The safety assessment is conducted by identifying adverse events (AEs) and lab test abnormalities. Treatment-related adverse events was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.

Results. The therapy with aTPO-r was effective in 49 (84 %) patients, including 36 patients (84 %) treated with romiplostim and 13 patients (87 %) with eltrombopag. The median dose to maintain a response was 3.7 mg/kg and 44 mg, respectively. A stable remission was achieved in 4 patients after discontinuation of romiplostim and 1 patient after discontinuation of eltrombopag. aTPO-r resistance was diagnosed in 9 (16 %) patients: 7 (16 %) of them were from the romiplostim group and 2 (13 %) from the eltrombopag group. Complete arrest of bleeding was achieved in 43 (88 %) responders and its reduction to grade I was achieved in the remaining 6 (12 %) of them. The most frequent AEs of romiplostim therapy were headache, arthralgia and dermatitis; and the treatment with eltrombopag caused hepatotoxicity, headache, and nausea. The severity of events did not lead to complete discontinuation of the therapy in any case. Different types of thrombotic complications were diagnosed in 3 patients (5.2 %).

Conclusion. The therapy with aTPO-r is an effective and safe method for the treatment of patients with chronic ITP in the second and subsequent lines of therapy.

Keywords: immune thrombocytopenia, idiopathic thrompocytopenic purpura, romiplostim, eltrombopag.

Received: July 27, 2016

Accepted: November 25, 2016

Read in PDF (RUS)pdficon

REFERENCES

  1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86. doi: 10.1182/blood-2009-06-225565.
  2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standartization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93. doi: 10.1182/blood-2008-07-162503.
  3. Масчан А.А., Румянцев А.Г., Ковалева Л.Г. и др. Рекомендации российского совета экспертов по диагностике и лечению больных первичной иммунной тромбоцитопенией. Онкогематология. 2010;3:36–45.
    [Maschan AA, Rumyantsev AG, Kovaleva LG, et al. Guidelines of Russian expert council on diagnostic and therapy of patients with primary immune thrombocytopenia. Onkogematologiya. 2010;3:36–45. (In Russ)]
  4. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207. doi: 10.1182/blood-2010-08-302984.
  5. Меликян А.Л., Пустовая Е.И., Цветаева Н.В. и др. Национальные клинические рекомендации по диагностике и лечению первичной иммунной тромбоцитопении (идиопатической тромбоцитопенической пурпуры) у взрослых. Гематология и трансфузиология. 2015;60(1):44–56.
    [Melikyan AL, Pustovaya EI, Tsvetaeva NV, et al. National clinical recommendations for diagnosis and therapy of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) in adults. Gematologiya i transfuziologiya. 2015;60(1):44–56. (In Russ)]
  6. Ковалева Л.Г., Сафонова Т.И., Пустовая Е.И. и др. Клинико-статистические данные и оценка различных методов терапии идиопатической тромбоцитопенической пурпуры. Терапевтический архив. 2011;4:60–5.
    [Kovaleva LG, Safonova TI, Pustovaya EI, et al. Clinical statistic data and evaluation of different methods of treatment of idiopathic thrombocytopenic purpura. Terapevticheskii arkhiv. 2011;4:60–5. (In Russ)]
  7. Kuter DJ. Milestones in understanding platelet production: a historical overview. Br J Haematol. 2014;165(2):248–58. doi: 10.1111/bjh.12781.
  8. Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4–13. doi: 10.1160/Th07-08-0513.
  9. Nurden AT, Viallard JF, Nurden P, et al. New generation drags that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet. 2009;373(9674):1562–9. doi: 10.1016/S0140-6736(09)60255-5.
  10. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoietin stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672–81. doi: 10.1056/NEJMoa054626.
  11. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic immune thrombocytopenic purpura: a randomised double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641–8. doi: 10.1016/S0140-6736(09)60402-5.
  12. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. doi: 10.1016/S0140-6736(08)60203-2.
  13. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized, phase 3 study. Lancet. 2011;377(9763):393–402. doi: 10.1016/S0140-6736(10)60959-2.
  14. Kuter DJ, Bussel JB, Newland AC, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23. doi: 10.1111/bjh.122260.
  15. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45. doi: 10.1182/blood-2012-04-425512.
  16. Bussel JB, Rodeghiero F, Lyons R, et al. Sustained hemostatic platelet counts in adults with chronic immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases. Blood (ASH Annual Meeting Abstracts). 2011;118(21): Abstract 3281.
  17. Carpendo M, Cantoni S, Coccini V. et al. Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice. Hematol Rep. 2015;7(1):5673. doi: 10.4081/hr.2015.5673.
  18. Mahevas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Hematol. 2014;165(6):865–9. doi: 10.1111/bjh.12888.
  19. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338–45. doi: 10.1182/blood-2011-03-340166.
  20. Лисуков И.А., Масчан А.А., Шамардина А.В. и др. Иммунная тромбоцитопения: клинические проявления и ответ на терапию. Промежуточный анализ данных Российского регистра пациентов с первичной иммунной тромбоцитопенией и обзор литературы. Онкогематология. 2013;2:61–9.
    [Lisukov IA, Maschan AA, Shamardina AV, et al. Immune thrombocytopenia: clinical manifestation and therapy response. The interim analysis of data from Russian registry of patients with primary immune thrombocytopenia and literature review. Onkogematologiya. 2013;2:61–9. (In Russ)]
  21. Птушкин В.В., Миненко С.В., Биячуев Э.Р. и др. Лечение больных с резистентной иммунной тромбоцитопенией: обзор литературы и клинические наблюдения. Онкогематология. 2011;1:56–63. doi: 10.17650/1818-8346-2011-6-1-56-63.
    [Ptushkin VV, Minenko SV, Biyachuev ER, et al. Treatment of patients with refractory immune thrombocytopenia: literature review and case report. Onkogematologiya. 2011;1:56–63. doi: 10.17650/1818-8346-2011-6-1-56-63. (In Russ)]
  22. Kuter DJ, Macahiling C, Grotzinger KM, et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015,101(3):255–63. doi: 10.1007/s12185-014-1731-7.
  23. Зотова И.И., Абдулкадыров К.М. Опыт применения ромиплостима при хронической иммунной тромбоцитопении, резистентной к предшествующей терапии. Гематология и трансфузиология. 2012;57(3):48–9.
    [Zotova II, Abdulkadyrov KM. Experience in application of romiplostim in chronic immune thrombocytopenia resistant to prior therapy. Gematologiya i transfuziologiya. 2012;57(3):48–9. (In Russ)]
  24. Abdulkadyrov K, Zotova I. The effectiveness and safety of the thrombopoietin (TPO) reсeptor agonists in the treatment of adults with chronic immune thrombocytopenia (ITP) refractory to other treatments. Haematologica. 2013;98(Suppl 1): Abstract B1923.
  25. Zotova I, Abdulkadyrov K. Romiplostim: efficacy and safety in patients with immune thrombocytopenia (ITP). Single center experience. Haematologica. 2014;99(Suppl 1): Abstract P614.
  26. Zotova I, Gritsaev S, Shilova E, et al. Thrombopoietin reсeptor agonists in the treatment of primary ITP: experience of application in clinical practice one medical center. Haematologica. 2016;101(Suppl 1): Abstract PB2091.
  27. Fogarty PF, Tarantino MD, Brainsky A, et al. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012;28(1):79–87. doi: 10.1185/03007995.2011.644849.
  28. Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-reсeptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937–44. doi: 10.3324/haematol.2013.098921.
  29. Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from EXTEND study. Am J Hematol. 2015;90(7):598–601. doi: 10.1002/ajh.24011.